Biosimilar ranibizumab (BS1) - early experience from Japan (BRIJ study).
作者信息
Ueda-Consolvo Tomoko, Ishida Masaaki, Nakamura Tomoko, Yanagisawa Shuichiro, Tsuboi Kotaro, Wakabayashi Taku, Hayashi Atsushi, Sharma Ashish
机构信息
Department of Ophthalmology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan.
Department of Ophthalmology, Aichi Medical University, Nagakute, Aichi, Japan.
出版信息
Eye (Lond). 2024 Nov;38(16):3193-3196. doi: 10.1038/s41433-024-03220-z. Epub 2024 Jul 23.
Abstract
摘要
相似文献
1
Biosimilar ranibizumab (BS1) - early experience from Japan (BRIJ study).生物类似药雷珠单抗（BS1）——来自日本的早期经验（BRIJ研究）。
Eye (Lond). 2024 Nov;38(16):3193-3196. doi: 10.1038/s41433-024-03220-z. Epub 2024 Jul 23.
2
Cost-effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration and its Subtypes from the Societal and Patient Perspectives in Japan.从日本社会和患者角度看雷珠单抗生物类似药治疗新生血管性年龄相关性黄斑变性及其亚型的成本效益分析
Ophthalmol Ther. 2024 Oct;13(10):2629-2644. doi: 10.1007/s40123-024-01011-z. Epub 2024 Aug 10.
3
Safety and efficacy of Razumab™ (world's first biosimilar ranibizumab) in wet age-related macular degeneration: a post-marketing, prospective ASSET study.Razumab™（全球首个雷珠单抗生物类似药）治疗湿性年龄相关性黄斑变性的安全性和有效性：一项上市后前瞻性ASSET研究。
Int J Retina Vitreous. 2021 Mar 24;7(1):24. doi: 10.1186/s40942-021-00293-w.
4
CompaRative Safety Analysis of Innovator and BioSimilar Ranibizumab in Chorioretinal Vascular Diseases - The CRsIBS Study.创新型雷珠单抗与生物类似药雷珠单抗在脉络膜视网膜血管疾病中的比较安全性分析——CRsIBS研究
Clin Ophthalmol. 2025 Mar 28;19:1093-1102. doi: 10.2147/OPTH.S515479. eCollection 2025.
5
Innovator ranibizumab ComparEd to Biosimilar ranibizumab in combination with Expansile gas in submaculaR HemorrhaGe: the ICEBERG study.在黄斑下出血中，创新型雷珠单抗与生物类似药雷珠单抗联合膨胀性气体的比较：冰山研究
BMC Ophthalmol. 2025 Jan 23;25(1):41. doi: 10.1186/s12886-025-03846-x.
6
Changing trends in the use of anti-vascular endothelial growth factor (anti-VEGF) biosimilars: Insights from the Vitreoretinal Society of India Biosimilars of Anti-VEGF Survey.抗血管内皮生长因子（anti-VEGF）生物类似药使用变化趋势：来自印度玻璃体视网膜学会抗 VEGF 生物类似药调查的见解。
Indian J Ophthalmol. 2021 Feb;69(2):352-356. doi: 10.4103/ijo.IJO_2703_20.
7
Comparison Between Ranibizumab Biosimilar, Innovator Ranibizumab and Bevacizumab in a Real-World Situation.雷珠单抗生物类似药、原研雷珠单抗与贝伐单抗在真实世界中的比较
Ophthalmol Ther. 2022 Feb;11(1):135-149. doi: 10.1007/s40123-021-00416-4. Epub 2021 Nov 5.
8
Clinical efficacy and safety of Razumab® (CESAR) study: Our experience with the world's first biosimilar Ranibizumab.Razumab®（CESAR）研究的临床疗效和安全性：我们使用全球首个生物类似药雷珠单抗的经验。
Indian J Ophthalmol. 2021 Feb;69(2):347-351. doi: 10.4103/ijo.IJO_2516_20.
9
Biosimilar Ranibizumab (Ranieyes) Safety and Efficacy in the Real World: BRESER Study.生物类似药雷珠单抗（Ranieyes）在现实世界中的安全性和有效性：BRESER研究
J Vitreoretin Dis. 2025 Feb 27:24741264251322213. doi: 10.1177/24741264251322213.
10
Efficacy and Safety of Biosimilar FYB201 Compared with Ranibizumab in Neovascular Age-Related Macular Degeneration.生物类似药 FYB201 对比雷珠单抗治疗新生血管性年龄相关性黄斑变性的疗效和安全性。
Ophthalmology. 2022 Jan;129(1):54-63. doi: 10.1016/j.ophtha.2021.04.031. Epub 2021 May 3.
引用本文的文献
1
Quantitative Assessment of En‑face OCT‑Derived Minimum Intensity Fluid Changes Following Ranibizumab Biosimilar Therapy in Macular Neovascularization Secondary to nAMD and PCV.雷珠单抗生物类似药治疗继发于湿性年龄相关性黄斑变性（nAMD）和息肉状脉络膜血管病变（PCV）的黄斑新生血管后，基于频域光学相干断层扫描（En-face OCT）的最小强度液体变化的定量评估
Clin Ophthalmol. 2025 Jul 29;19:2505-2512. doi: 10.2147/OPTH.S542496. eCollection 2025.
2
Aflibercept 2 mg biosimilar (Tyalia)-real-world experience from IRAN (ATRIA study).阿柏西普2毫克生物类似药（Tyalia）——来自伊朗的真实世界经验（ATRIA研究）
Eye (Lond). 2025 May 3. doi: 10.1038/s41433-025-03813-2.
3
Biosimilar Ranibizumab (Ranieyes) Safety and Efficacy in the Real World: BRESER Study.生物类似药雷珠单抗（Ranieyes）在现实世界中的安全性和有效性：BRESER研究
J Vitreoretin Dis. 2025 Feb 27:24741264251322213. doi: 10.1177/24741264251322213.
本文引用的文献
1
Biosimilars for retinal diseases: United States-Europe awareness survey (Bio-USER - survey).视网膜疾病生物类似药：美国-欧洲认知度调查（Bio-USER调查）
Expert Opin Biol Ther. 2023 Jul-Dec;23(8):851-859. doi: 10.1080/14712598.2023.2176218. Epub 2023 Feb 19.
2
Approved biosimilar ranibizumab-a global update.已批准的雷珠单抗生物类似药——全球最新情况
Eye (Lond). 2023 Feb;37(2):200-202. doi: 10.1038/s41433-022-02246-5. Epub 2022 Sep 16.
3
Real-Life Clinical Effectiveness of Razumab® (the World's First Biosimilar of Ranibizumab) in Retinal Vein Occlusion: A Subgroup Analysis of the Pooled Retrospective RE-ENACT Study.雷珠单抗生物类似药Razumab®（全球首个雷珠单抗生物类似药）在视网膜静脉阻塞中的真实临床疗效：汇总回顾性RE-ENACT研究的亚组分析
Ophthalmologica. 2019;241(1):24-31. doi: 10.1159/000488602. Epub 2018 Jun 26.
Zotero 插件